Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525774 | 1.00 | IRAK4 (0.44) | IRAK4KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL4241916 | 0.93 | KDM4E (0.51) | IRAK4KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL17582866 | 0.93 | KDM4E (0.47) | IRAK4KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL8250121 | 0.86 | KDM4E (0.53) | IRAK4KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL20571609 | 0.85 | KDM4E (0.39) | IRAK4KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL22050060 | 0.84 | KDM4E (0.38) | IRAK4KDM4EGAAALDH1A1 | |
| SCHEMBL20572044 | 0.84 | PDE1B (0.39) | IRAK4KDM4EGAAALDH1A1EGLN2 | |
| SCHEMBL20571411 | 0.83 | KDM4E (0.37) | IRAK4KDM4EGAAALDH1A1 | |
| SCHEMBL21401111 | 0.81 | KDM4E (0.38) | IRAK4KDM4EGAAALDH1A1 | |
| SCHEMBL4636443 | 0.80 | IRAK4 (0.47) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| US-20250296925-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2025-09-25 | — | — | US | disclosed |
| US-12358893-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-07-15 | — | — | US | disclosed |
| EP-3562306-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2025-02-26 | — | — | EP | disclosed |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) | 2024-03-05 | — | — | US | disclosed |
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| EP-3908319-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-10-18 | — | — | EP | disclosed |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2018-07-05 | — | — | US | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125800-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125799-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (BERMUDA), LTD. (BM) | 2018-07-05 | — | — | WO | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382226-B2 | Aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-28 | — | — | US | disclosed |
| EP-2595482-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012478-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358893-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | IRAK4 4090/4885KDM4E 3875/4885GAA 4/4885 |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | IRAK4 3904/4885KDM4E 2641/4885GAA 139/4885 |
| US-20250296925-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | IRAK4 4090/4885KDM4E 3875/4885GAA 4/4885 |
| US-20180186773-A1 | METALLOENZYME INHIBITOR COMPOUNDS | SOD1, RNASE1, FECH | IRAK4 4090/4885KDM4E 3875/4885GAA 4/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | IRAK4 3649/4885KDM4E 1581/4885GAA 5/4885 |
| US-20130317057-A1 | ALDOSTERONE SYNTHASE INHIBITORS | HSD11B1, CYP11B2, HSD11B2 | IRAK4 4523/4885KDM4E 3294/4885GAA 2500/4885 |
| US-11919883-B2 | Metalloenzyme inhibitor compounds | SOD1, RNASE1, FECH | IRAK4 4090/4885KDM4E 3875/4885GAA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.